Given our current finding of Smurf1 in protecting the liver from steatosis, a viable strategy to treat NAFLD may be to curtail the transcriptional activity of PPARγ by turning on Smurf1-mediated non-proteolytic ubiquitin modification. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.